Platform for engineering oncolytic viruses that precisely target and destroy cancer cells with high selectivity.
Humane Genomics engineers cancer-killing viruses with a two-factor authentication approach—selective infection and selective replication—achieving an on-target to off-target kill ratio greater than 1000. The company is developing its first indication in pediatric liver cancer (hepatoblastoma) in partnership with Texas Children's Hospital and has partnered with Genezen for cGMP manufacturing of its lead oncolytic virus candidate. Humane Genomics is a product of Humane Genomics.